Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Phase 2 PLATCOV results show oral ensitrelvir accelerates SARS‑CoV‑2 clearance versus no drug and has antiviral effects close to ritonavir‑boosted nirmatrelvir, supporting further phase 3 evaluation.
This review synthesizes evidence from Rwanda’s 2024 Marburg virus disease outbreak, highlighting epidemiologic characteristics, clinical presentations, investigational therapeutics, and vaccine deployment strategies that contributed t
An 18‑month booster of the VLA15 Lyme vaccine candidate produced strong anamnestic anti‑OspA IgG responses exceeding primary‑series levels in children, adolescents, and adults, with a tolerability profile similar to primary doses.
This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies an
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑
A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not c
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
The Infectious Diseases Society of America now recommends annual high-dose or adjuvanted influenza vaccine and a single RSV dose for most immunocompromised persons; timing around immunosuppression and household immunization are emphasized.
A phase 3 trial of Pfizer’s quadrivalent modified mRNA influenza vaccine (n≈18,476) showed 34.5% relative efficacy vs a licensed inactivated vaccine for laboratory-confirmed influenza (A strains) with higher reactogenicity but low rates of
A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑repo
Emerging H3N2 subclade K has driven increased influenza activity abroad and may seed the 2025–26 northern hemisphere season. Surveillance gaps complicate risk assessment; vaccination and early antiviral use remain central clinical strategie
An adult male in Washington has tested positive for avian flu, marking a resurgence after 9 months. This article explores the scientific evidence, recent outbreaks, and practical advice to prevent infection.
A Phase III trial of ganaplacide‑lumefantrine (GanLum, KLU156) met its primary non‑inferiority endpoint vs artemether‑lumefantrine, with a PCR‑corrected Day‑29 cure rate of 97.4% (estimand). The drug combines a novel mechanism (ganaplacide)
A 37-year-old man developed meningoencephalitis caused by a novel mammarenavirus genetically related to Lassa virus after travel to Chad, highlighting emergence of a new pathogen with distinct clinical features.
Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.
The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation consideration
In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑ma
Open language-specific specialty feeds and department pages.